Press Releases

AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis

AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status CAMBRIDGE, Mass. --(BUSINESS WIRE)-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S.

Mar 09, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of

Mar 05, 2020

AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the Cowen and Company 40 th

Feb 24, 2020

AVROBIO Announces Closing of Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock.

Feb 18, 2020

AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share.

Feb 12, 2020

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.

Feb 12, 2020

AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program

Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures Data from the Phase 1 and Phase 2 trials of AVR-RD-01 support potential long-term engraftment and durable, endogenous production of functional

Feb 10, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Feb 06, 2020

AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020

Analyst and investor event to be webcast on Monday, Feb. 10, 2020 , at 7:00 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2020-- AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that

Feb 04, 2020

AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program

FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato ™ platform CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.

Jan 14, 2020



Displaying 21 - 30 of 31

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.